Verquvo – Heart Failure – DUPLICATE DEAL – 56028

Heart failure with preserved ejection fraction (HFpEF) is an increasingly common source of morbidity, with very few specific modalities available for treatment. While pharmacologically reducing cardiac pacing with beta-blockers...

Quadruple therapy is cost-effective for HFrEF, according to results published in JACC: Heart Failure. Gregg Fonarow, MD, and colleagues assessed 1,000 simulated patients with HFrEF, comparing quadruple therapy versus triple and...

Long-term exposure to ambient fine particulate matter (PM2.5) correlates with an increased need for diagnostic testing in HF, according to findings published in PLOS ONE. Cavin K. Ward-Caviness, PhD, and colleagues found that,...

The previous ANTWOORD I study evaluated the ANTWERP score, which predicts left ventricular ejection fraction (LVEF) recovery after ablation in patients with HF and AF, scoring patients who have one or more of the following four...

Adaptive cardiac resynchronisation therapy (CRT) did not reduce the risk for death or intervention for heart failure (HF) decompensation compared with conventional CRT in patients with HF, left bundle branch block (LBBB), and...